The Australian Securities and Investments Commission has won leave to appeal to the High Court a ruling that threw out its case against former directors of collapsed retirement village owner Prime Trust.
Not to be outdone by other class action firms vying to recruit AMP shareholders for a $2 billion class action, Slater & Gordon announced Friday it would offer investors “the most competitive funding package of all”.
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company’s founder and her lawyers from DLA Piper.
The ACCC won its case against Sydney-based Unique International College on a “paucity of material”, the Full Federal Court has heard in an appeal of a ruling that found the vocational trainer exploited disadvantaged people and violated the Australian Consumer Law.
The Australian Competition and Consumer Commission has raised concerns that the proposed $2 billion acquisition of Sydney toll road WestConnex by toll road operator Transurban may stymie competition for toll road projects in Australia.
Optus was ordered Wednesday to temporarily pull an ad that Telstra alleges makes a false and damaging claim about the superiority of Optus’ mobile network.
The financing arrangement underwriting Quinn Emanuel’s shareholder class action against AMP, which will earn its partner Burford Capital a record low 10 percent of any recovery, sets a new standard in class action litigation funding, and is expected to spark greater price competition in the industry.
The Full Federal Court has slapped Japanese car parts maker Yazaki Corporation with a $46 million penalty for colluding with a competitor on prices for wire harnesses supplied to Toyota, handing a win to the ACCC which argued the original $9.5 million penalty handed down did not reflect the seriousness of the conduct.
Drug giant F. Hoffman-La Roche asked the Federal Court Tuesday for an order barring the release of a generic version of its blockbuster cancer drug MabThera by a unit of Swiss rival Novartis, which it claims could lead to “tens of millions of dollars” in losses.
A bidding war erupted Tuesday among law firms angling to lead a $2 billion shareholder class action against AMP, with Maurice Blackburn announcing a “super deal” and Quinn Emanuel besting that with a funding arrangement to “shake up” the market.